| Pfizer AG - Vyndaqel 20 mg, Weichkapseln | | 67083 | | 01 | | Vyndaqel 20 mg | | Weichkapseln | | N07XX08 | | Tafamidis | | 05.03.2020 | | |
| | Composition | | tafamidisum megluminum 20 mg corresp. tafamidisum 12.2 mg, macrogolum 400, polysorbatum 80, sorbitani oleas, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (flavum), E 171, Drucktinte: macrogolum 400, propylenglycolum, polyvinylis acetas phtalas, E 120, E 133, pro capsula. | | Packungsbestandteile | | Capsules molles | | | | Principe actif | Concentr. |
|---|
| Tafamidisum Megluminum | 20 mg correspond Tafamidisum 12.2 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Flavum) | | | | E 120 | | color. | | E 133 | | color. | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Glycerol | | | | Macrogol | 400 | Drucktinte | | Polysorbatum 80 | | | | Polyvinylis Acetas Phtalas | | | | Pro Capsula | | | | Propylenglycol | | | | Sorbitani Oleas | | | | Sorbitolum Liquidum Partim Deshydricum | | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 30 | | | B | | Non |
|
|
